1. Home
  2. TSHA vs SAM Comparison

TSHA vs SAM Comparison

Compare TSHA & SAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$5.66

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Boston Beer Company Inc. (The)

SAM

Boston Beer Company Inc. (The)

HOLD

Current Price

$170.75

Market Cap

1.9B

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSHA
SAM
Founded
2019
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Beverages (Production/Distribution)
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.9B
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
TSHA
SAM
Price
$5.66
$170.75
Analyst Decision
Strong Buy
Hold
Analyst Count
8
11
Target Price
$11.63
$233.70
AVG Volume (30 Days)
4.1M
284.3K
Earning Date
05-06-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
5.56
95.45
EPS
N/A
N/A
Revenue
$9,773,000.00
$1,964,994,000.00
Revenue This Year
N/A
$1.02
Revenue Next Year
$1,152.42
$1.31
P/E Ratio
N/A
N/A
Revenue Growth
17.28
N/A
52 Week Low
$2.53
$158.68
52 Week High
$7.30
$264.46

Technical Indicators

Market Signals
Indicator
TSHA
SAM
Relative Strength Index (RSI) 43.52 43.68
Support Level $5.28 $166.36
Resistance Level $6.01 $188.80
Average True Range (ATR) 0.45 7.32
MACD -0.10 0.10
Stochastic Oscillator 24.09 18.51

Price Performance

Historical Comparison
TSHA
SAM

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

About SAM Boston Beer Company Inc. (The)

Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.

Share on Social Networks: